全反式维甲酸对EVI1过表达的高危急性髓系白血病的疗效
Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1.
作者信息
Paubelle Etienne, Plesa Adriana, Hayette Sandrine, Elhamri Mohamed, Zylbersztejn Florence, Hermine Olivier, Salles Gilles, Thomas Xavier
机构信息
Department of Clinical Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.
Faculté de Médecine Lyon-Sud Charles Mérieux, Université de Lyon, Pierre Bénite, France.
出版信息
Oncol Ther. 2019 Dec;7(2):121-130. doi: 10.1007/s40487-019-0095-9. Epub 2019 May 22.
INTRODUCTION
EVI1 (MECOM)-positive acute myeloid leukemia (AML) cells have shown in vitro sensitivity to all-trans-retinoic acid (ATRA) by inducing differentiation, cell death, and decreased leukemic engraftment.
METHODS
In this pilot study, we investigated the response to ATRA in 13 high-risk AML patients with overexpression of EVI1.
RESULTS
Seven of the 13 patients (53.8%) achieved complete remission (CR), and response can be combined with a decreased of the leukemia stem cell pool.
CONCLUSION
These primary results tend to confirm in vitro results and suggest that addition of ATRA might be of benefit in the treatment of patients with EVI1-positive AML.
引言
EVI1（MECOM）阳性急性髓系白血病（AML）细胞通过诱导分化、细胞死亡和减少白血病植入，在体外显示出对全反式维甲酸（ATRA）敏感。
方法
在这项初步研究中，我们调查了13例EVI1过表达的高危AML患者对ATRA的反应。
结果
13例患者中有7例（53.8%）实现完全缓解（CR），且反应可伴有白血病干细胞池的减少。
结论
这些初步结果倾向于证实体外实验结果，并表明添加ATRA可能对治疗EVI1阳性AML患者有益。
Zotero 插件